title: Heat shock protein vaccines against glioblastoma: from bench to bedside.
abstract: Current adjuvant treatment regimens available for the treatment of glioblastoma are widely ineffective and offer a dismal prognosis. Advancements in conventional treatment strategies have only yielded modest improvements in overall survival. Immunotherapy remains a promising adjuvant in the treatment of GBM through eliciting tumor specific immune responses capable of producing sustained antitumor response while minimizing systemic toxicity. Heat shock proteins (HSP) function as intracellular chaperones and have been implicated in the activation of both innate and adaptive immune systems. Vaccines formulated from HSP-peptide complexes, derived from autologous tumor, have been applied to the field of immunotherapy for glioblastoma. The results from the phase I and II clinical trials have been promising. Here we review the role of HSP in cellular function and immunity, and its application in the treatment of glioblastoma.
authors.affiliation: Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, 676 N. St. Clair Street, Suite 20-250, Chicago, IL, 60611-2911, USA.
authors.forename: Leonel
authors.initials: L
authors.lastname: Ampie
authors.forename: Winward
authors.initials: W
authors.lastname: Choy
authors.forename: Jonathan B
authors.initials: JB
authors.lastname: Lamano
authors.forename: Shayan
authors.initials: S
authors.lastname: Fakurnejad
authors.forename: Orin
authors.initials: O
authors.lastname: Bloch
authors.forename: Andrew T
authors.initials: AT
authors.lastname: Parsa
mesh_terms: D000818:Animals; D001932:Brain Neoplasms / Q000276:immunology / Q000628:therapy*; D019496:Cancer Vaccines / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005909:Glioblastoma / Q000276:immunology / Q000628:therapy*; D006360:Heat-Shock Proteins / Q000276:immunology*; D006801:Humans; D057170:Translational Research, Biomedical
chemical_list: D019496:Cancer Vaccines; D006360:Heat-Shock Proteins